Personalis

55 articles with Personalis

• Personalis, Inc. to Present at Advances in Immuno-Oncology Congress USA 2019

  10/8/2019

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Advances in Immuno-Oncology Congress USA 2019 in San Diego on October 8th at 2:50 PM PDT.

• Personalis Receives New Order from the VA’s Million Veteran Program – Total Awarded to Date Now $145M

  9/26/2019

  Personalis, Inc. announced a new task order under its contract with the U.S. Department of Veterans Affairs for the VA’s Million Veteran Program.

• Personalis Appoints Karin Eastham to Its Board of Directors

  9/12/2019

  Personalis, Inc., a leader in advanced genomics for cancer, announced that it has appointed Karin Eastham as an independent director to its Board of Directors.

• Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial

  9/9/2019

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has entered into a research agreement with Invectys, a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers

• Personalis to Participate in the 17th Annual Morgan Stanley Global Healthcare Conference

  8/26/2019

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company will participate at the upcoming 17th Annual Morgan Stanley Global Healthcare Conference being held from September 9-11, 2019 in New York, NY.

• Personalis Reports Second Quarter 2019 Financial Results

  8/13/2019

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the second quarter ended June 30, 2019.

• Personalis, Inc. to Provide Comprehensive Tumor Immunogenomic Profiling to the New Mexico Cancer Care Alliance for Clinical Study

  8/7/2019

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that The University of New Mexico (UNM) Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care will utilize Personalis’ cancer immunogenomics platform, ImmunoID NeXT™

• Personalis, Inc. Announces Integration of New ImmunoID NeXT Platform™ Features in Latest Expansion of Immuno-Oncology Biomarker Discovery Applications

  8/1/2019

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of its universal cancer immunogenomics platform, ImmunoID NeXT, incorporating several additional features that are pivotal to the understanding of tumor and immune cell interactions and how the nature of these interactions can impact cancer patients’ ability to respond to immunotherapies and combination therapies.

• Personalis to Announce Second Quarter 2019 Financial Results on August 13, 2019

  7/30/2019

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its second quarter 2019 financial results after the market closes on Tuesday, August 13, 2019.

• Personalis Announces Closing of Initial Public Offering and Exercise in Full of Over Allotment Option

  6/24/2019

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the closing of its initial public offering of 9,109,725 shares of common stock at a public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,188,225 additional shares of common stock.

• 

  Six Biotech Companies with IPOs This Week

  6/21/2019

  This week marked initial public offering news from six biopharma companies. Here’s a look.

• Personalis Prices Initial Public Offering of Common Stock

  6/20/2019

  Personalis, Inc., a leader in advanced genomics for cancer, announced the pricing of its initial public offering of 7,921,500 shares of common stock at a price to the public of $17.00 per share.

• Personalis, Inc. to Provide Tumor Immunogenomic Profiling to the Parker Institute for Immunotherapy Biomarker Discovery in Clinical Trial Participants

  5/22/2019

  This project builds on Personalis’ existing relationship with the Parker Institute as a contributing industry member of the TESLA Consortium, which focuses on improving neoantigen prediction algorithms.

• Personalis Enters into a Research Agreement with FLX Bio to Provide Comprehensive Tumor Immunogenomic Profiling for Clinical Study

  5/20/2019

  Cutting Edge Platform Enables the Detection of Changes in the Tumor Microenvironment Following Treatment with FLX475

• Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 2019

  5/20/2019

  Personalis, Inc., a leader in advanced genomics for cancer, announced that the company will present at Advances in Immuno-Oncology Congress UK 2019 in London on May 21st at 11:00 AM BST.

• Personalis, Inc. to Present at European NeoAG Summit 2019

  4/23/2019

  Personalis, Inc., a leader in advanced genomics for cancer, today announced that the company will present at European NeoAG Summit 2019 in Amsterdam on April 24th at 2:30 PM CEST.

• Personalis Appoints Industry Executive Aaron Tachibana as Chief Financial Officer

  4/2/2019

  Personalis a leader in advanced genomics for cancer, today announced the appointment of Aaron Tachibana as Chief Financial Officer.

• Personalis, Inc. to Present at the American Association for Cancer Research (AACR) Annual Meeting 2019

  3/31/2019

  Personalis, Inc., a leader in advanced genomics for cancer, announced that the company will present one oral presentation and five posters at the American Association for Cancer Research Annual Meeting being held this year in Atlanta, GA from March 31 – April 3, 2019.

• Personalis, Inc. to Present at ICI-IO Combinations Summit 2019

  3/18/2019

  Personalis, Inc., a leader in advanced genomics for precision oncology, today announced that they are scheduled to present at ICI-IO Combinations Summit 2019 in Boston on Wednesday, March 20, 2019 at 2:30 PM, EDT.

• Personalis, Inc. to Present at the World Immunotherapy Congress USA 2019

  2/28/2019

  Personalis, Inc., a leader in advanced genomics for precision oncology, announced that they are scheduled to present at the upcoming World Immunotherapy Congress USA, which is part of the Festival of Biologics USA, in San Diego on Tuesday, March 5, 2019 at 2:20 PM, PST.